ISGylation governs the oncogenic function of Ki-Ras in breast cancer

Oncogene

Volumn 33, Issue 6, 2014, Pages 794-803

  Burks, J ^a   Reed, R E ^a   Desai, S D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; ISG15; ISGylation; Ki Ras; oncogenic transformation; UbcH8

Indexed keywords

SHORT HAIRPIN RNA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CELL PROLIFERATION; CHEMICAL REACTION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; INTERFERON STIMULATED GENE 15; ISGYLATION; MALIGNANT TRANSFORMATION; ONCOGENE; ONCOGENE KIRSTEN RAS; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; AUTOPHAGY; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; FEMALE; GENE EXPRESSION; GENES, RAS; HUMANS; MICE; MUTATION; NIH 3T3 CELLS; RAS PROTEINS; UBIQUITINS;

EID: 84893644001     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.633     Document Type: Article

References (53)

1. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 2006; 94: 1465-1471.
2. Andersen JB, Hassel BA. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? Cytokine Growth Factor Rev 2006; 17: 411-421.
3. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A et al. The ubiquitinlike molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res 2008; 10: R58.
4. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 2006; 66: 921-928.
5. Haas AL, Ahrens P, Bright PM, Ankel H. Interferon induces a 15-kilodalton protein exhibitingmarked homology to ubiquitin. J Biol Chem 1987; 262: 11315-11323.
6. Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L et al. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene 2009; 28: 2606-2620.
7. Nielsch U, Pine R, Zimmer SG, Babiss LE. Induced expression of the endogenous beta interferon gene in adenovirus type 5-transformed rat fibroblasts. J Virol 1992; 66: 1884-1890.
8. Tsai YC, Pestka S, Wang LH, Runnels LW, Wan S, Lyu YL et al. Interferon-beta signaling contributes to Ras transformation. PLoS ONE 2011; 6: e24291.
9. Hummer BT, Li XL, Hassel BA. Role for p53 in gene induction by double-stranded RNA. J Virol 2001; 75: 7774-7777.
10. Wood LM, Sankar S, Reed RE, Haas AL, Liu LF, McKinnon P et al. A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway. PLoS ONE 2011; 6: e16422.
11. Tripathi MK, Chaudhuri G. Down-regulation of UCRP and UBE2L6 in BRCA2 knocked-down human breast cells. Biochem Biophys Res Commun 2005; 328: 43-48.
12. Harty RN, Pitha PM, Okumura A. Antiviral activity of innate immune protein ISG15. J Innate Immun 2009; 1: 397-404.
13. Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL et al. ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood) 2012; 237: 38-49.
14. Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F et al. Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target. Mol Cancer Ther 2012; 9: 1968-1977.
15. Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 2004; 64: 8109-8115.
16. McLaughlin PM, Helfrich W, Kok K, Mulder M, Hu SW, Brinker MG et al. The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines. Int J Cancer 2000; 85: 871-876.
17. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. Mol Cancer 2003; 2: 15.
18. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005; 386: 193-205.
19. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993; 260: 85-88.
20. Friedman E, Verderame M, Winawer S, Pollack R. Actin cytoskeletal organization loss in the benign-to-malignant tumor transition in cultured human colonic epithelial cells. Cancer Res 1984; 44: 3040-3050.
21. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007; 5: 195-201.
22. Eckert LB, Repasky GA, Ulkü AS, McFall A, Zhou H, Sartor CI et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004; 64: 4585-4592.
23. Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP et al. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 2007; 67: 8460-8467.
24. Kim SE, Yoon JY, Jeong WJ, Jeon SH, Park Y, Yoon JB et al. H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation. J Cell Sci 2009; 122: 842-848.
25. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21: 245-273.
26. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995; 7: 215-223.
27. Ciechanover A. Early work on the ubiquitin proteasome system, an interview with Aaron Ciechanover. Interview by CDD. Cell Death Differ 2005; 12: 1167-1177.
28. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007; 315: 201-205.
29. Lauwers E, Jacob C, Andre B. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J Cell Biol 2009; 185: 493-502.
30. Pickart CM. Targeting of substrates to the 26S proteasome. FASEB J 1997; 11: 1055-1066.
31. Pickart CM. Ubiquitin in chains. Trends Biochem Sci 2000; 25: 544-548.
32. Takeuchi T, Yokosawa H. ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activity. Biochem Biophys Res Commun 2005; 336: 9-13.
33. Zou W, Papov V, Malakhova O, Kim KI, Dao C, Li J et al. ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem Biophys Res Commun 2005; 336: 61-68.
34. Zou W, Wang J, Zhang DE. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem Biophys Res Commun 2007; 354: 321-327.
35. Takeuchi T, Iwahara S, Saeki Y, Sasajima H, Yokosawa H. Link between the ubiquitin conjugation system and the ISG15 conjugation system: ISG15 conjugation to the UbcH6 ubiquitin E2 enzyme. J Biochem 2005; 138: 711-719.
36. Lu A, Tebar F, Alvarez-Moya B, Ló pez-Alcalá C, Calvo M, Enrich C et al. A clathrindependent pathway leads to KRas signaling on late endosomes en route to lysosomes. J Cell Biol 2009; 184: 863-879.
37. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998; 23: 33-42.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
40. Jacobsen K, Groth A, Willumsen BM. Ras-inducible immortalized fibroblasts: focus formation without cell cycle deregulation. Oncogene 2002; 21: 3058-3067.
41. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008; 8: 835-850.
42. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326.
43. Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S et al. Tumourassociated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999; 18: 4301-4312.
44. Begum R, Nur EKMS, Zaman MA. The role of Rho GTPases in the regulation of the rearrangement of actin cytoskeleton and cell movement. Exp Mol Med 2004; 36: 358-366.
45. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-2623.
46. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237: 178-182.
47. Scott N, Bell SM, Sagar P, Blair GE, Dixon MF, Quirke P. p53 expression and K-ras mutation in colorectal adenomas. Gut 1993; 34: 621-624.
48. Farassati F, Bell SM, Sagar P, Blair GE, Dixon MF, Quirke P. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol 2008; 173: 1861-1872.
49. Shim JH, Xiao C, Hayden MS, Lee KY, Trombetta ES, Pypaert M et al. CHMP5 is essential for late endosome function and down-regulation of receptor signaling during mouse embryogenesis. J Cell Biol 2006; 172: 1045-1056.
50. Pincetic A, Kuang Z, Seo EJ, Leis J. The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J Virol 2011; 84: 4725-4736.
51. Kuang Z, Seo EJ, Leis J. Mechanism of inhibition of retrovirus release from cells by interferon-induced gene ISG15. J Virol 2011; 85: 7153-7161.
52. Ward DM, Vaughn MB, Shiflett SL, White PL, Pollock AL, Hill J et al. The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cells. J Biol Chem 2005; 280: 10548-10555.
53. Yin X, Cong X, Yan M, Zhang DE. Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung Cancer 2009; 63: 194-200.